ClinicalTrials.gg
RecruitingNCT07947498MI-HolterUpdated Nov 19, 2026

Prognostic Value of 2-Week ECG Monitoring After PCI in Acute Myocardial Infarction

An interventional study of MEMO Patch2 in Acute Myocardial Infarction (AMI), ST Elevation Myocardial Infarction and Non-ST Elevation Myocardial Infarction, sponsored by Chungnam National University Hospital. Recruiting at 1 site in South Korea. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by Chungnam National University Hospital · Not applicable, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Registered 2 years 3 months after the study started (first participant enrolled Aug 2024, registered Nov 2026).
  • Started Aug 2024; still recruiting 2 years 3 months later.
Updated Nov 19, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
300
Allocation
Not applicable
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 36 studies in ST Elevation Myocardial Infarction with a site in Korea, Republic of — 8 open to participants now, 12 under way, 2 of them phase 3. ST Elevation Myocardial Infarction · Korea, Republic of.

Planned enrollment
16th of 28
300 · median 314
Started
2024
with 1 other
No phase
14 of 36
5 open now
Primary completion
2026-12
later than 3 of 11 live
Registered
36th of 36
by date

Among the 36 studies in ST Elevation Myocardial Infarction with a site in Korea, Republic of, this one is the 16th largest by planned enrollment of the 28 interventional ones that give a count, is one of 2 that started in 2024, is one of 14 with no phase, reaches primary completion later than 3 of the 11 other live ones, and was the 36th registered.

ST Elevation Myocardial Infarction

855 studies on the registry are indexed under ST Elevation Myocardial Infarction; 200 are open to participants now.

Browse ST Elevation Myocardial Infarction studies →

Open to participants now

8 of the 36 studies in ST Elevation Myocardial Infarction with a site in Korea, Republic of are open now. Recruiting first, the newest first:

2 more — sign in →

All 8 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 122 ST Elevation Myocardial Infarction studies recruiting now, 76 (62%) set no upper age limit and 20 (16%) stop at 75 or younger; 10 take children under 18; 9 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies in ST Elevation Myocardial Infarction with a site in Korea, Republic of, or all of them as a file.
02

Study summary

This single-center, single-group study will evaluate the prognostic value of long-term electrocardiographic monitoring in adults with acute myocardial infarction who undergo primary percutaneous coronary intervention. After written informed consent, eligible participants will have a MEMO Patch2 long-term Holter monitor applied on the day of, or the day after, the procedure and will wear it for 2 weeks. The study will classify high-risk arrhythmias detected during monitoring and compare long-term clinical outcomes according to arrhythmia classification.

Read the detailed description

Patients presenting with acute myocardial infarction and undergoing primary percutaneous coronary intervention will be screened at Chungnam National University Hospital. Eligible adults who understand the study and provide written informed consent will be enrolled.

A MEMO Patch2 long-term Holter monitor will be attached on the day of, or the day after, the procedure. Participants will wear the device for 2 weeks and have it removed at an outpatient visit, after which the electrocardiographic recordings will be analyzed. Recorded arrhythmias include ventricular tachycardia, ventricular fibrillation, nonsustained ventricular tachycardia, atrial fibrillation, atrial flutter, high-degree atrioventricular block, and ventricular premature complexes.

The primary objective is to classify high-risk arrhythmias detected by 2-week monitoring. The secondary objective is to compare long-term prognosis according to arrhythmia classification, including all-cause death, cardiac death, noncardiac death, rehospitalization for heart failure, recurrent myocardial infarction, and stroke. Baseline diseases, laboratory results, social history, coronary intervention findings, prescribed medications, height, weight, and body mass index will also be collected. Statistical analyses described in the Protocol include descriptive statistics, t-tests, chi-square tests, Pearson correlation, multiple regression, multiple Cox regression, and Kaplan-Meier survival analysis, with a two-sided significance level of p\<0.05.

03

Conditions studied

  • Acute Myocardial Infarction (AMI)
  • ST Elevation Myocardial Infarction
  • Non-ST Elevation Myocardial Infarction
  • Cardiac Arrhythmias

Keywords

  • Acute myocardial infarction (AMI)
  • Primary percutaneous coronary intervention (pPCI)
  • Long-term Holter monitoring
  • MEMO Patch2
  • Ventricular arrhythmia
  • Atrial fibrillation
  • High-degree atrioventricular block
  • Major adverse cardiovascular event (MACE)
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult aged 20 years or older.
  • Diagnosed with STEMI and underwent primary percutaneous coronary intervention; or diagnosed with NSTEMI, underwent primary percutaneous coronary intervention, and meets at least one of the following conditions: (a) ≤45% on echocardiography; (b) ventricular tachycardia, ventricular fibrillation, atrial fibrillation, or high-degree atrioventricular block during or after percutaneous coronary intervention (ventricular tachycardia is defined as ≥3 consecutive ventricular premature complexes); or (c) post-procedural TIMI flow grade 0-2 during percutaneous coronary intervention.
  • Has received and understood an explanation of the study and signed the form.

Exclusion criteria

Exclusion Criteria:

  • Refuses to participate in the study.
  • Is transferred to another hospital immediately after the procedure and cannot be followed.
  • Is unable to express an intention to participate in the study, such as due to unconsciousness.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
300 participants (estimated)

Study arms

  • Experimental
    MEMO Patch2 Long-Term Holter Monitoring

    Participants with acute myocardial infarction who undergo primary percutaneous coronary intervention will have a MEMO Patch2 long-term Holter monitor attached on the day of, or the day after, the procedure. The device will be worn continuously for 2 weeks and removed at an outpatient visit. Recorded arrhythmias will be analyzed, and long-term prognosis will be compared according to arrhythmia classification.

    Device: MEMO Patch2

Interventions

  • DeviceMEMO Patch2

    MEMO Patch2 is a detachable long-term Holter monitoring device. It will be applied on the day of, or the day after, primary percutaneous coronary intervention and worn for 2 weeks to record arrhythmias that may be missed by in-hospital monitoring. It will be removed at an outpatient visit, and the recordings will then be analyzed.

    Also known as: Long-term Holter monitor

06

What researchers measure

Primary outcomes

  1. Classification of High-Risk Arrhythmias

    High-risk arrhythmias detected by MEMO Patch2 will be classified. Arrhythmias assessed include ventricular tachycardia, ventricular fibrillation, nonsustained ventricular tachycardia, atrial fibrillation, atrial flutter, high-degree atrioventricular block, and ventricular premature complexes.

    Time frame: At the outpatient visit after completion of the 2-week MEMO Patch2 monitoring period

Secondary outcomes

  1. Long-Term Prognosis According to Arrhythmia Classification

    Long-term prognosis will be compared according to arrhythmia classification. Outcomes include all-cause death, cardiac death, noncardiac death, rehospitalization for heart failure, recurrent myocardial infarction, and stroke.

    Time frame: Through study completion (anticipated 2026-12-31)

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — Individual participant data collected in this study are not planned to be shared with external researchers. Any future sharing would require separate sponsor approval and compliance with applicable privacy, ethical, and institutional requirements.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2024 (actual). Primary completion is estimated for Dec 2026, 28 months after the start.

Of 134 non-industry interventional studies with no phase under ST Elevation Myocardial Infarction, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 64. This study's planned 28 months is below that.

Counting every sponsor, half of 143 studies reached it within 38 months; a quarter within 19 and three quarters within 64.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 12, 2026
First posted
Nov 19, 2026
StartActual
Aug 2, 2024
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07947498
Lead sponsor
Chungnam National University Hospital
Collaborators
HUINNO Co., Ltd
Responsible party
Junhyung Kim (Associate Professor, Department of Internal Medicine, Chungnam National University Hospital) — Principal investigator
First posted
Nov 19, 2026
Start date
Aug 2, 2024
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Nov 19, 2026

Study contacts

JunHyung Kim
Contact
william@cnu.ac.kr
+82-042-280-8237

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion